Introduction
============

Ewing sarcoma is the second most common primary bone sarcoma. It is an orphan state disease with approximately 900 new diagnoses a year in Europe \[[@B1]\]. It is also called the Ewing Sarcoma Family of Tumours (ESFT) and includes Ewing sarcoma of bone, extra-osseous Ewing sarcoma, Primitive Neuroectodermal (PNET) and Askin\'s tumours. Ewing sarcoma is diagnostically defined by a Ewing sarcoma EWS (chromosome 22) translocation resulting in fusion with an ETS transcription factor, the commonest abnormality (85%) being EWS-FLI1 (chromosome 11). Ewing sarcoma is a disease affecting children and young adults with a peak incidence at age fifteen. With current treatment options the 5 year survival for non-metastatic disease is 60-70%. However, survival for the 25% of patients that present with metastatic disease is approximately 20% \[[@B2]\], and for those who develop relapsed and/or refractory disease, the survival is no more than 10%.

Current patients are subdivided by disease stage, namely non-metastatic, metastatic and recurrence, and patients in each group are treated the same. But apparently this subdivision is not always related to clinical outcome, because of the patients who present with non-metastatic disease, approximately 30% die within 5 years. This group may be currently undertreated while the 70% who survive may be over-treated. It may therefore be important to separate the high risk patients from the low risk patients and to be able to detect chemotherapy resistance and metastases early.

A way of predicting patients\' outcome is by using prognostic factors. The most commonly used are clinical features, eg age, gender, metastases. Biomarker is a synonym for biological markers and is defined as \"a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processor or pharmacologic responses to a therapeutic intervention\" \[[@B3]\]. Biomarkers are currently already being used for screening, diagnosis, prognosis and monitoring of cancer patients. In 2005 the Reporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines were published \[[@B4]\]. The goal of these guidelines is to make the results from clinical prognostic studies transparent and to improve the level of comparison that is possible between studies.

We report an overview of the research which has been done to identify reliable biomarkers for Ewing sarcoma in the past 15 years, where we detail the kind of markers that have been tested, the number of patients involved and the p-value showing the significance of the marker. The results highlight some interesting biomarkers, but they have yet to be validated.

Materials and methods
=====================

Search strategy
---------------

We report data available in the public domain only. Papers were identified from PubMed searches and from references in the found articles. The search algorithm was: (Ewing sarcoma) AND (prognostic factors) OR (biomarker). Only papers published between 1995 and 2010 are included. The latest search was done in June 2010. Whenever multiple reports from the same study were published, we used only the report with the latest published date to avoid any duplication of information. Papers were eligible if they: (1) described (or cited a paper that described) a Ewing sarcoma study of prognostic factors or biomarkers; (2) were published in English; and (3) came from industrialized countries. All types of evaluation were accepted (full papers, conference abstracts, reports) as long as results (including data) were presented.

Data extraction
---------------

Data extraction was conducted independently by the first author (A.M. v. M.). We used a systematic method for the search normally used for meta-analysis \[[@B5]\]. Differences in data extraction were resolved by consensus with a second author (A.B.H). From each eligible trial we recorded authors\' names, journal and year of publication and the results from the study.

Results and Discussion
======================

Eligible trials
---------------

A flow-chart indicating the identification of reports for inclusion in the analysis is reported for Ewing sarcoma (Figure [1](#F1){ref-type="fig"}). During the search many reports had to be excluded mainly because no prognostic markers were reported in the article. When we searched the reports using full text, we had to exclude some papers because no Ewing sarcoma patients were included in these reports. We identified 86 articles which were eligible for our search criteria. In these papers a total of 11, 625 patients were reported.

![**Flowchart for the identification of eligible reports**.](2045-3329-2-7-1){#F1}

In this report we looked at the published data on the use of biomarkers for the last 15 years. Biomarkers were grouped into phenotypic markers and biological markers. Markers were taken as statistically significant if p \< 0.05. For phenotypic markers we reported the outcome for gender, tumour size, presence of metastases and histological response after treatment (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} &[4](#T4){ref-type="table"}). We showed the p-value reported in the eligible articles and the distribution of p correlated to the number of patients (Figures [2](#F2){ref-type="fig"}). There doesn\'t seem to be a relationship between the number of patients and the p-value. For example, the distribution of histological response shows that the studies with small patient numbers have the same statistical significance as these with large patient numbers. Throughout this report, the assumption is that the biomarker has a linear relationship to outcome. We know that for many biomarkers, this is not the case. For example, data transformation using either bicubic splines or fractional polynomials is often required to correlate continuous relationships between biomarkers and outcome, as opposed to predefined cutpoints \[[@B6]\]. We can only have limited extrapolation of the reported data to outcome as in most instances these questions have not been addressed.

###### 

Outcome for phenotypic marker: gender

  Author                                                             Year   Pt number   P
  ------------------------------------------------------------------ ------ ----------- -------
  Craft et al, Eur J Cancer 33 (7), 1061-9\[[@B8]\]                  1997   142         0.3
                                                                                        
  Aparicio et al, Oncology 55, 20-6 \[[@B9]\]                        1998   116         NS
                                                                                        
  Ahrens et al, Med Pediatr Oncol 32, 186-95 \[[@B10]\]              1999   177         0.92
                                                                                        
  Ginsberg et al, J Clin Oncol 17, 1809-14\[[@B11]\]                 1999   85          0.79
                                                                                        
  Givens et al, Int J Oncol 14 (6), 1039-43\[[@B12]\]                1999   85          NS
                                                                                        
  Bacci et al, J Clin Oncol 18, 4-11\[[@B13]\]                       2000   359         0.02
                                                                                        
  Jenkin et al, Med Pediatr Oncol 37, 383-9\[[@B14]\]                2001   93          0.73
                                                                                        
  Krasin et al, Cancer 104, 367-73\[[@B15]\]                         2005   33          0.25
                                                                                        
  Bacci et al, Acta Oncol 45, 469-75\[[@B16]\]                       2006   579         0.03
                                                                                        
  De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52\[[@B17]\]   2007   24          NS
                                                                                        
  Leavey et al, Pediatr Blood Cancer 51 (3), 334-8\[[@B18]\]         2008   262         0.05
                                                                                        
  Jawad et al, Cancer 115, 3526-36\[[@B19]\]                         2009   1631        0.004
                                                                                        
  Kikuta et al, Clin Cancer Res 15 (8), 2885-94\[[@B20]\]            2009   8           0.53
                                                                                        
  Sari et al, Pediatr Blood Cancer 54, 19-24\[[@B21]\]               2010   87          0.04
                                                                                        
  Xie et al, Chin J Cancer 29 (4), 420-4                             2010   18          0.36

NS: not significant

###### 

Outcome for phenotypic marker: tumour size

  Author                                                          Year   Pt number   P
  --------------------------------------------------------------- ------ ----------- --------
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                      1998   116         0.0016
                                                                                     
  Kawai et al, Cancer 82, 851-9\[[@B22]\]                         1998   20          0.0038
                                                                                     
  Ahmad et al, Cancer 85, 725-31\[[@B23]\]                        1999   24          0.277
                                                                                     
  Givens et al Int J Oncol 14 (6), 1039-43\[[@B12]\]              1999   85          NS
                                                                                     
  Cotterill et al, J Clin Oncol 18, 3108-14\[[@B24]\]             2000   975         0.001
                                                                                     
  De Alava et al, Cancer 89, 783-92\[[@B25]\]                     2000   55          0.02
                                                                                     
  Jenkin et al, Med Pediatr Oncol 37, 383-9\[[@B14]\]             2001   93          0.0001
                                                                                     
  Oberlin et al, B J Cancer 85 (11), 1646-54\[[@B26]\]            2001   141         0.002
                                                                                     
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]               2003   13          0.05
                                                                                     
  Krasin et al, Pediatr Blood Cancer 43, 229-36\[[@B28]\]         2004   37          S
                                                                                     
  Matsunobu et al, Clin Cancer Res 10, 1003-12\[[@B29]\]          2004   21          0.05
                                                                                     
  Krasin et al, Cancer 104, 367-73\[[@B28]\]                      2005   33          0.25
                                                                                     
  Aksnes et al, Acta Oncol 45, 38-46\[[@B30]\]                    2006   56          0.001
                                                                                     
  Bacci et al, Acta Oncol 45, 469-75\[[@B16]\]                    2006   579         0.0004
                                                                                     
  Mikulic et al, J Pediatr Surg 41, 524-9\[[@B31]\]               2006   27          0.031
                                                                                     
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]        2007   28          NS
                                                                                     
  Rodriguez-Galindo et al, Ann Oncol 19, 814-20\[[@B33]\]         2008   220         0.018
                                                                                     
  Yonemori et al, J Cancer Res Clin Oncol 134, 389-95\[[@B34]\]   2008   79          S
                                                                                     
  Jawad et al, Cancer 115, 3526-36\[[@B19]\]                      2009   1631        0.001
                                                                                     
  Kikuta et al, Clin Cancer Res 15 (8), 2885-94\[[@B20]\]         2009   8           0.018
                                                                                     
  Lee et al, Cancer 116, 1964-73\[[@B35]\]                        2010   725         0.001
                                                                                     
  Xie et al, Chin J Cancer 29 (4), 420-4                          2010   18          0.44

NS: not significant, S: significant

###### 

Outcome for phenotypic marker: metastases

  Author                                                            Year   Pt number   P
  ----------------------------------------------------------------- ------ ----------- --------
  Terrier et al, Eur J Cancer 31 (3), 307-14\[[@B36]\]              1995   315         0.003
                                                                                       
  Terrier et al, Semin Diagn Pathol 13 (3), 250-7\[[@B37]\]         1996   315         S
                                                                                       
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                        1998   116         0.03
                                                                                       
  De Alava et al, J Clin Oncol 16 (4), 1248-55\[[@B38]\]            1998   99          0.008
                                                                                       
  Paulussen et al, J Clin oncol 16 99), 3044-52\[[@B39]\]           1998   114         S
                                                                                       
  Ahmad et al, Cancer 85, 725-31\[[@B23]\]                          1999   24          0.219
                                                                                       
  Baldini et al, Ann Surg 230 (1), 79-86\[[@B40]\]                  1999   37          0.002
                                                                                       
  Ginsberg et al, J Clin Oncol 17, 1809-14\[[@B11]\]                1999   85          0.33
                                                                                       
  Luksch et al, Tumori 85 (2), 101-7\[[@B41]\]                      1999   73          S
                                                                                       
  Cotterill et al, J Clin Oncol 18, 3108-14\[[@B24]\]               2000   975         0.0001
                                                                                       
  De Alava et al, Cancer 89, 783-92\[[@B25]\]                       2000   55          0.02
                                                                                       
  Wei et al, Cancer 89, 793-9\[[@B42]\]                             2000   39          0.001
                                                                                       
  Jenkin et al, Med Pediatr Oncol 37, 383-9\[[@B14]\]               2001   93          0.04
                                                                                       
  Zielenska et al, Cancer 91, 2156-64\[[@B43]\]                     2001   26          0.0137
                                                                                       
  Martin et al, Arch Surg 138, 281-5\[[@B44]\]                      2003   59          0.02
                                                                                       
  Fuchs et al, Clin Cancer Res 10, 1344-53\[[@B45]\]                2004   31          0.022
                                                                                       
  Matsunobu et al, Clin Cancer Res 10, 1003-12\[[@B29]\]            2004   21          NS
                                                                                       
  Weston et al, B J Cancer 91, 225-32\[[@B46]\]                     2004   385         0.001
                                                                                       
  Aksnes et al, Acta Oncol 45, 38-46\[[@B30]\]                      2006   56          0.001
                                                                                       
  Kreuter, Eur J Cancer 45, 1904-11\[[@B47]\]                       2006   40          S
                                                                                       
  La et al, Int J Radiat Oncol Biol Phys 64 (2), 544-50\[[@B48]\]   2006   60          0.036
                                                                                       
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]          2007   28          0.04
                                                                                       
  Leavey et al, Pediatr blood Cancer 51 (3), 334-8\[[@B18]\]        2008   262         0.02
                                                                                       
  Yonemori et al, J Cancer Res Clin Oncol 134, 389-95\[[@B34]\]     2008   79          0.02
                                                                                       
  Jawad et al, Cancer 115, 3526-36\[[@B19]\]                        2009   385         0.001
                                                                                       
  Sari et al, Pediatr Blood Cancer 54, 19-24\[[@B21]\]              2010   87          0.001
                                                                                       
  Xie et al, Chin J Cancer 29 (4), 420-4                            2010   18          0.01

NS: not significant, S: significant

###### 

Outcome for phenotypic marker: histological response

  Author                                                      Year   Pt number   P
  ----------------------------------------------------------- ------ ----------- --------
  Delepine et al, J Chemother 9 (5), 352-63\[[@B49]\]         1997   39          0.05
                                                                                 
  Picci et al, J Clin Oncol 15 (4), 1553-9\[[@B50]\]          1997   118         0.0001
                                                                                 
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                  1998   116         0.018
                                                                                 
  Paulussen et al, J Clin Oncol 16 (9), 3044-52\[[@B39]\]     1998   114         S
                                                                                 
  Abudu et al, J Bone Joint Surg 81 (2), 317-22\[[@B51]\]     1999   50          0.03
                                                                                 
  Ahrens et al, Med Pediatr Oncol 32, 186-95\[[@B10]\]        1999   177         0.27
                                                                                 
  Baldini et al, Ann Surg 230 (1), 79-86\[[@B40]\]            1999   37          0.01
                                                                                 
  Bacci et al, J Clin Oncol 18, 4-11\[[@B13]\]                2000   359         0.001
                                                                                 
  De Alava et al, Cancer 89, 783-92\[[@B25]\]                 2000   55          0.001
                                                                                 
  Ohali et al, J Clin Oncol 21, 3836-43\[[@B52]\]             2003   31          0.0001
                                                                                 
  Scotlandi et al, Eur J Cancer 41, 1349-61\[[@B53]\]         2005   113         0.05
                                                                                 
  Bacci et al, Acta Oncol 45, 469-75\[[@B16]\]                2006   579         0.0005
                                                                                 
  Mikulic et al, J Pediatr Surg 41, 524-9\[[@B31]\]           2006   27          0.047
                                                                                 
  Avigad et al, Clin Cancer Res 13 (19), 5777-83\[[@B54]\]    2007   32          0.13
                                                                                 
  Yonemori, J Cancer Res Clin Oncol 134, 389-95v \[[@B34]\]   2008   79          0.04
                                                                                 
  Meynet et al, Cancer Res 70 (9), 3730-8\[[@B55]\]           2010   97          0.02

S: significant

![**Distribution of p related to patient number for the phenotypic markers: gender, tumour size, metastases and histological response**. The red line shows the cut-off point of p = 0.05.](2045-3329-2-7-2){#F2}

Primary outcome
---------------

The investigated biomarkers are subdivided in two groups, phenotypic markers and biological markers. For the phenotypic markers gender, tumour size, metastases and histological response are reported in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. For all these phenotypic markers we compared the patient number and p-value, in which p \< 0.05 was taken as statistically significant. However we weren\'t able to retrieve the p-value in all articles, sometimes it was only mentioned as being significant or non-significant. For each phenotypic marker we looked at the differences in overall survival between: for gender, men vs women; for tumour size, \< 8-10 cm vs \> 8- 10 cm; for metastasis presence at initial presentation vs absence and for histological response, \> 90% necrosis vs \< 90% necrosis. Distributions of p related to patient numbers in these four phenotypic markers are shown in Figures [2](#F2){ref-type="fig"}. For these four phenotypic markers we show that there is no correlation between the number of patients and the statistical significance of the outcome. More phenotypic markers were reported: fusion type, ethnicity, performance status and margins. However because of the low number of studies which reported these outcomes these results are not shown in detail. In 26 articles the impact of tumour site on the overall survival is shown, but because sites are compared in different ways it is difficult to summarize these findings.

Currently clinical stage is being used to determine whether a patient has a high or low risk for developing metastases or recurrence. However, it seems that clinical stage is not always related to outcome, because of the patients who present with non-metastatic disease, only 70% of them survive for 5-years. Therefore, what is the difference between the 70% of the patients who survive and the 30% who don\'t? Can one somehow foretell chemotherapy resistance and detect metastases early? One way to predict the outcome of patients apart from clinical stage is to use biomarkers. These are objective measurements which reflect biological processes. The biomarkers currently being used are tumour size and the presence of metastases. Biological markers are not being used, even though they may provide a way to predict a patient\'s outcome more accurately than phenotypic markers. From the results for phenotypic markers we can see that gender is probably not significant important for patient outcome. In 15 articles we found 11 reports that gender is non-significant. Tumour size \> 8 cm seems to be important, with 15 out of 22 articles finding it to be a predictor and significantly related to negative outcome. The presence of metastasis is a strong predictor of negative outcome with 24 articles reporting it as significantly relevant compared to only 3 reporting it as non-significant. For histological response, 12 out of 16 articles found that necrosis \> 90% after treatment is a significant predictor for positive outcome.

For some phenotypic markers it is unclear how the cut-off point between predictor of positive or negative outcomes is determined. For tumour size the cut-off point for negative outcome is \> 8 cm, but it is undefined how this is selected. It seems more logical that tumour size is a continuous variable with an increasingly negative outcome with increasing size. The same can probably be said for age and surgical margins.

Biological markers are more difficult to compare, because for most of these markers only one or two reports are published. We grouped the biological markers according to their function and we ended up with 5 groups, namely cell cycle, karyotype, immunological, blood products and the remaining biological markers which couldn\'t be classified in one of the other groups. The results from the biological markers are shown in Tables [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}, [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}. The correlation between patient number and statistical significance of the outcome for the five groups is shown in Figures [3](#F3){ref-type="fig"}. We show that there is no correlation between the patient number and the statistical significance of the outcome. It appears that ki67, an S-phase cell cycle biomarker, may be a biomarker of cell activity in the tumour that significantly correlates with outcome. The mechanism for the activation of cell cycle appears unclear, but is presumably driven by other factors other that EWS-FLI1 translocation. Loss of function of cell cycle dependent kinases (p16, p14, p21) and other regulators of the cell cycle through the p53 pathway (MDM2, p53), also appear deregulate in a proportion of tumours and potentially are useful prognostic markers. Importantly, activity of telomerase appears significantly correlated with outcome as occurs in many other tumours. There appears much interest in secondary copy number changes and mutations in Ewing sarcoma, and in particular, chromosome 1 (Table [6](#T6){ref-type="table"}). For example, recent evidence points to gain of 1q and alteration in abundance of a gene product called CDt2 involved in ubiquitination \[[@B7]\]. It is however difficult to objectively say anything about the other reported markers because they may influence each other. This appears most clear for tumour size and metastases, where bigger tumours may correlate with a higher chance of having metastases. For biological markers it is probably the same issue, but less clear because we don\'t really know their true experimental influence on tumour genesis. For example, LDH levels are probably a reflection of cell turnover in larger tumours, and may be an indirect measure of bulk of disease (comparing Table [2](#T2){ref-type="table"} versus Table [9](#T9){ref-type="table"}). It is also more difficult to say anything about biological markers because they haven\'t been tested as extensively as phenotypic markers, and certainly they have not often been validated independently. Results for most of these markers are only reported in 1 or 2 articles with sometimes small numbers of patients and no statistical validation. To improve this situation it would important to capture high quality clinical material and clinical outcome to develop a bio-bank. We may be able to test the most promising biomarkers from previously run studies and so define their significance. Either a multivariate analysis or data mining analysis should be done to evaluate the way biomarkers affect each other. The easiest way to achieve this objective is by collecting material and outcome data from large phase III trials. It is also important to standardize the way material is collected and how the biomarkers are compared. For example, the phenotypic marker tumour site is the most often tested marker with results published in 26 articles (data not shown). However it is not possible to say anything about these results since different tumour sites are compared in the reports. This is also true for the marker age in which different age groups are compared with each other, for example some articles compare patients \< 18 years vs \> 18 years, others \< 30 years vs \> 30 years (data not shown).

###### 

Outcome for biological markers: cell cycle

  Author                                                     Year   Biomarker         Pt number   P
  ---------------------------------------------------------- ------ ----------------- ----------- --------
  Landanyi et al, J Pathol 175 (2), 211-7                    1995   MDM-2             30          0.005
                                                                                                  
  Luksch et al, Tumori 85 (2), 101-7\[[@B41]\]               1999   Mitose presence   73          S
                                                                                                  
  Sollazzo et al, tumori 85 (3), 167-73\[[@B56]\]            1999   Ki-67             38          0.01
                                                                                                  
  De Alava et al, Cancer 89, 783-92\[[@B25]\]                2000   Ki-67             55          0.005
                                                                                                  
  Abudu et al, Br J Cancer 79(7-8), 1185-9\[[@B57]\]         1999   P53               50          0.02
                                                                                                  
  Huang et al, J Clin Oncol 23, 548-58\[[@B58]\]             2005   P53               60          0.001
                                                                                                  
  Matsunobu et al, C;in Cancer Res 10, 1003-12\[[@B29]\]     2004   P27               21          0.01
                                                                                                  
  Wei et al, Cancer 89, 793-9\[[@B42]\]                      2000   INK4a             39          0.001
                                                                                                  
  Maitra et al, Arch Pathol Lab Med 125, 1207-12\[[@B59]\]   2001   P16INK4a          20          0.41
                                                                                                  
  Maitra et al, Arch Pathol Lab Med 125, 1207-12\[[@B59]\]   2001   P14ARF            20          NS
                                                                                                  
  Huang et al, J Clin Oncol 23, 548-58\[[@B58]\]             2005   P16/p14ARF        60          0.03
                                                                                                  
  Maitra et al, Arch Pathol Lab Med 125, 1207-12\[[@B59]\]   2001   P21WAF1           20          0.61
                                                                                                  
  Ohali et al, Oncogene 23, 8997-9006\[[@B60]\]              2004   Cadherin-11       20          0.024
                                                                                                  
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]   2007   STEAP1            28          0.0012
                                                                                                  
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]   2007   CCND1             28          0.0077
                                                                                                  
  Martins et al, Cancer Res 68 (15), 6260-70\[[@B61]\]       2008   Heat shock 90     54          S
                                                                                                  
  Zanini et al, Virchows Arch 452, 157-67\[[@B62]\]          2008   Heat shock 27     unknown     NS

S: significant, NS: not significant

###### 

Outcome for biological markers: karyotype

  Author                                                                Year   Biomarker             Pt number   P
  --------------------------------------------------------------------- ------ --------------------- ----------- --------
  Tarkannen et al, Cancer Genet Cytogenet 114, 35-41                    1999   1q                    28          NS
                                                                                                                 
  Hattinger et al, Br J Cancer 86, 1763-9\[[@B63]\]                     2002   1q                    134         0.046
                                                                                                                 
  Tarkannen et al, Cancer Genet Cytogenet 114, 35-41                    1999   6p2.1                 28          0.004
                                                                                                                 
  Lopez-Guerrero et al, Lab Invest 81 (6), 803-14\[[@B64]\]             2001   9p21 locus            19          0.005
                                                                                                                 
  Hattinger et al, Br J Cancer 86, 1763-9\[[@B63]\]                     2002   16q                   134         0.008
                                                                                                                 
  Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54\[[@B65]\]    1999   Chr 1                 58          0.004
                                                                                                                 
  Tarkannen et al, Cancer Genet Cytogenet 114, 35-41                    1999   Chr 8                 28          NS
                                                                                                                 
  Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54\[[@B65]\]    1999   Chr 8                 58          0.17
                                                                                                                 
  Hattinger et al, Br J Cancer 86, 1763-9\[[@B63]\]                     2002   Chr 8                 134         NS
                                                                                                                 
  Tarkannen et al, Cancer Genet Cytogenet 114, 35-41                    1999   Chr 12                28          NS
                                                                                                                 
  Hattinger et al, Genes Chromosomes Cancer 24 (3), 243-54 \[[@B65]\]   1999   Chr 12                58          0.63
                                                                                                                 
  Hattinger et al, Br J Cancer 86, 1763-9\[[@B63]\]                     2002   Chr 12                134         0.009
                                                                                                                 
  Ohali et al, J Clin Oncol 21, 3836-43\[[@B52]\]                       2003   Telomerase activity   31          0.0001
                                                                                                                 
  Avigad et al, Clin Cancer Res 13 (19), 5777-83\[[@B54]\]              2007   Telomerase length     32          0.015

NS: not significant, Chr: Chromosome

###### 

Outcome for biological markers: immunological

  Author                                              Year   Biomarker     Pt number   P
  --------------------------------------------------- ------ ------------- ----------- --------
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   IL-1ra        13          0.0001
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   sIL-2ra       13          0.005
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   IL-6          13          0.001
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   IL-8          13          0.0001
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   IL-10         13          0.01
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   TNF RI        13          0.001
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   TNF RII       13          0.01
                                                                                       
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]   2003   M-CSF         13          0.01
                                                                                       
  Berghuis et al, J Pathol 218, 222-31\[[@B66]\]      2009   HLA class I   67          NS

NS: not significant

###### 

Outcome for biological markers: blood products

  Author                                                              Year   Biomarker                        Pt number   P
  ------------------------------------------------------------------- ------ -------------------------------- ----------- --------
  Holzer et al, Med Pediatr Oncol 36 (6), 601-4\[[@B67]\]             2001   VEGF                             6           NS
                                                                                                                          
  Pavlakovic et al, Int J Cancer 92, 756-60 \[[@B68]\]                2001   VEGF                             4           0.017
                                                                                                                          
  Rutkowski et al, J Surg Oncol 84, 151-9\[[@B27]\]                   2003   VEGF                             13          NS
                                                                                                                          
  Fuchs et al, Clin Cancer Res 10, 1344-53\[[@B45]\]                  2004   VEGF                             31          0.0047
                                                                                                                          
  Jimeno et al, Pediatr Blood Cancer 49, 352-7\[[@B69]\]              2007   VEGF                             16          NS
                                                                                                                          
  Kreuter et al, Eur J Cancer 42, 1904-11\[[@B47]\]                   2006   VEGF-A                           40          0.013
                                                                                                                          
  Kreuter et al, Eur J Cancer 42, 1904-11\[[@B47]\]                   2006   VEGFR-1                          40          0.946
                                                                                                                          
  Kreuter et al, Eur J Cancer 42, 1904-11\[[@B47]\]                   2006   VEGFR-2                          40          0.946
                                                                                                                          
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                          1998   Lymphocyte count                 116         0.0044
                                                                                                                          
  De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52\[[@B17]\]    2007   Lymphocyte count                 24          0.001
                                                                                                                          
  De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52 \[[@B17]\]   2007   Platelet count                   24          NS
                                                                                                                          
  De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52\[[@B17]\]    2007   Neutrophil count                 24          NS
                                                                                                                          
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                          1998   Erythrocyte sedimentation rate   116         0.02
                                                                                                                          
  Oberlin et al, B J Cancer 85 (11), 1646-54\[[@B26]\]                2001   Erythrocyte sedimentation rate   141         0.04
                                                                                                                          
  Yabe et al, Oncol Rep 19 (1), 129-34\[[@B70]\]                      2008   Erythrocyte sedimentation rate   20          NS

NS: not significant

###### 

Outcome for biological markers: remaining

  Author                                                       Year   Biomarker                  Pt number   P
  ------------------------------------------------------------ ------ -------------------------- ----------- --------
  Craft et al, Eur J Cancer 33 (7), 1061-9\[[@B8]\]            1997   LDH                        142         NS
                                                                                                             
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                   1998   LDH                        116         0.001
                                                                                                             
  Givens et al, Int J Oncol 14 (6), 1039-43\[[@B12]\]          1999   LDH                        85          NS
                                                                                                             
  Bacci et al, Oncol Rep 6 (4), 807-11\[[@B71]\]               1999   LDH                        618         S
                                                                                                             
  Luksch et al, Tumori 85 (2), 101-7\[[@B41]\]                 1999   LDH                        73          S
                                                                                                             
  Bacci et al, J Clin Oncol 18, 4-11\[[@B13]\]                 2000   LDH                        359         0.0003
                                                                                                             
  Matsunobu et al, Clin Cancer Res 10, 1003-12\[[@B29]\]       2004   LDH                        21          NS
                                                                                                             
  Bacci et al, Acta Oncol 45, 469-75\[[@B16]\]                 2006   LDH                        579         0.0005
                                                                                                             
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]     2007   LDH                        28          0.99
                                                                                                             
  Yabe et al, Oncol Rep 19 (1), 129-34\[[@B70]\]               2008   LDH                        20          NS
                                                                                                             
  Leavey et al, Pediatr Blood Cancer 51 (3), 334-8\[[@B18]\]   2008   LDH                        262         0.0016
                                                                                                             
  Xie et al, Chin J Cancer 29 (4), 420-4                       2010   LDH                        18          NS
                                                                                                             
  Terrier et al, Eur J Cancer 31 (3), 307-14\[[@B36]\]         1995   Filigree pattern           315         0.044
                                                                                                             
  Terrier et al, Eur J Cancer 31 (3), 307-14\[[@B36]\]         1995   Dark cells                 315         0.043
                                                                                                             
  Aparicio et al, Oncology 55, 20-6\[[@B9]\]                   1998   Albumine levels            116         0.0006
                                                                                                             
  Sollazzo et al, Tumori 85 (3), 167-73\[[@B56]\]              1999   c-myc                      38          S
                                                                                                             
  Ohali et al, Oncogene 23, 8997-9006\[[@B60]\]                2004   MTA1                       20          0.003
                                                                                                             
  Cheung et al, Clin Cancer Res 13 (23), 6978-83\[[@B32]\]     2007   NKX2-2                     28          0.0017
                                                                                                             
  Kikuta et al, Clin Cancer Res 15 (8), 2885-94\[[@B20]\]      2009   Nucleophosmin positivity   8           0.01
                                                                                                             
  Meynet et al, Cancer Res 70 (9), 3730-8\[[@B55]\]            2010   Xg expression              97          0.047

S: significant, NS: not significant

![**Distribution of p related to patient number for the biological markers related to cell cycle, karyotype, immunological, blood products and remaining markers**. The red line shows the cut-off point of p = 0.05. Note, there is no line for immunological phenotypic markers because for all the results p \< 0.05.](2045-3329-2-7-3){#F3}

For markers of tumour growth, angiogenesis if often quantified, but so far biomarker analysis has been predominantly limited to measurement of VEGF pathway (Table [8](#T8){ref-type="table"}). The immunological biological markers interleukins and tumour necrosis factors seem very promising (Table [7](#T7){ref-type="table"}). However these have all been tested in one institute, with very small patient numbers and the data doesn\'t seem to be validated. Most of the biological markers mentioned in the blood products group (Table [8](#T8){ref-type="table"}) are probably surrogates for tumour size and they should be validated in either a multivariate analysis or machine learning to see if they can be used as an objective biological marker.

At the present time it is no possible to make a definite list of biological biomarkers able to predict patient outcome, mainly because these markers also have to be stratified with respect to the major staging phenotypic features, e.g. presence of metastasis and degree of histological response. It is also unclear what quality control measure were used in the limited patient cohorts. Our recommendation would be continue divide patients according to their disease stage and also to use the phenotypic biomarkers metastasis, tumour size and histological response. For biological biomarkers we would like to validate previous work done on the markers for 9p21 locus and the involved genes and proteins, heat shock proteins, telomerase related markers, interleukins, tumour necrosis factors, VEGF pathway, lymphocyte count, MTA1, STEAP1, CCND1, MDM-2, Ki-67, p53, p27 and cadherin-11. At this time, neither phenotypic (clinical) or biological biomarkers are utilised in stratification of patients in clinical trials.
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